Cancer最新文献

筛选
英文 中文
Overall survival benefit of pembrolizumab plus chemoradiotherapy for patients with high-risk locally advanced cervical cancer. 派姆单抗联合放化疗治疗高危局部晚期宫颈癌患者的总生存获益
IF 6.1 2区 医学
Cancer Pub Date : 2025-01-15 DOI: 10.1002/cncr.35688
Mary Beth Nierengarten
{"title":"Overall survival benefit of pembrolizumab plus chemoradiotherapy for patients with high-risk locally advanced cervical cancer.","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35688","DOIUrl":"https://doi.org/10.1002/cncr.35688","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":"e35688"},"PeriodicalIF":6.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of obesity on outcome in children diagnosed with cancer in Canada: A report from Cancer in Young People in Canada. 肥胖对加拿大儿童癌症诊断结果的影响:一份来自加拿大年轻人癌症的报告。
IF 6.1 2区 医学
Cancer Pub Date : 2025-01-15 DOI: 10.1002/cncr.35673
Samuel Sassine, André P Ilinca, Hallie Coltin, Henrique Bittencourt, Uma Athale, Lynette Bowes, Josée Brossard, Sara Israels, Donna L Johnston, Ketan Kulkarni, Sarah McKillop, Meera Rayar, Roona Sinha, Tony Truong, Catherine Vézina, Laura Wheaton, Alexandra P Zorzi, Lillian Sung, Marie-Claude Pelland-Marcotte, Thai Hoa Tran
{"title":"Impact of obesity on outcome in children diagnosed with cancer in Canada: A report from Cancer in Young People in Canada.","authors":"Samuel Sassine, André P Ilinca, Hallie Coltin, Henrique Bittencourt, Uma Athale, Lynette Bowes, Josée Brossard, Sara Israels, Donna L Johnston, Ketan Kulkarni, Sarah McKillop, Meera Rayar, Roona Sinha, Tony Truong, Catherine Vézina, Laura Wheaton, Alexandra P Zorzi, Lillian Sung, Marie-Claude Pelland-Marcotte, Thai Hoa Tran","doi":"10.1002/cncr.35673","DOIUrl":"https://doi.org/10.1002/cncr.35673","url":null,"abstract":"<p><strong>Background: </strong>Childhood obesity can result in adverse health outcomes. The objectives of this study were to describe the prevalence of obesity and determine the association between obesity at cancer diagnosis and event-free survival (EFS) and overall survival (OS) in children diagnosed with cancer in Canada.</p><p><strong>Methods: </strong>The authors conducted a retrospective cohort study using the Cancer in Young People in Canada database, including all children with newly diagnosed cancer aged 2-18 years across Canada from 2001 to 2020. Obesity was defined as age-adjusted and sex-adjusted body mass index greater than or equal to the 95th percentile. Univariate and multivariable Cox proportional hazards models compared EFS and OS between patients with and without obesity at diagnosis.</p><p><strong>Results: </strong>In total, 11,291 patients were included, of whom 10.5% were obese at diagnosis. In multivariable models controlling for age, sex, ethnicity, neighborhood income quintile, treatment era, and cancer categories, obesity at diagnosis was independently associated with inferior EFS (adjusted hazard ratio [aHR], 1.16; 95% confidence interval [CI], 1.02-1.32; p = .02) and OS (aHR, 1.29; 95% CI, 1.11-1.49; p = .001). The adverse prognostic impact of obesity was particularly notable for acute lymphoblastic leukemia (ALL) and central nervous system (CNS) tumors. In children with ALL (n = 3458), obesity remained associated with inferior EFS (aHR, 1.55; p = .002) and OS (aHR, 1.75; p = .002) in multivariable analysis. In patients with CNS tumors (n = 2458), obesity was also associated with inferior EFS (aHR, 1.38; p = .008) and OS (aHR, 1.47; p = .004).</p><p><strong>Conclusions: </strong>In this population-based study, obesity at cancer diagnosis was independently associated with inferior survival across the entire cohort, and prominently in children with ALL and CNS tumors.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":"e35673"},"PeriodicalIF":6.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring the impact of a catchment area surveillance tool on cancer center adopters. 测量集水区监测工具对癌症中心采用者的影响。
IF 6.1 2区 医学
Cancer Pub Date : 2025-01-15 DOI: 10.1002/cncr.35710
Todd Burus, Caree R McAfee, Natalie P Wilhite, Pamela C Hull
{"title":"Measuring the impact of a catchment area surveillance tool on cancer center adopters.","authors":"Todd Burus, Caree R McAfee, Natalie P Wilhite, Pamela C Hull","doi":"10.1002/cncr.35710","DOIUrl":"10.1002/cncr.35710","url":null,"abstract":"<p><strong>Background: </strong>The University of Kentucky Markey Cancer Center developed the data gathering and visualization platform Cancer InFocus (CIF) as a solution for cancer center catchment area surveillance. CIF was released in June 2022 and made available for use to other institutions through a no-cost licensing agreement. The purpose of this study was to evaluate the impact CIF has had on cancer centers since its release.</p><p><strong>Methods: </strong>The authors adapted an existing management evaluation framework to assess the impact of CIF across three spheres-idea dissemination, product engagement, and adopter satisfaction. This assessment included an online survey administered between the dates of September 18, 2023 and June 22, 2024 among 28 individuals at 13 CIF adopting institutions.</p><p><strong>Results: </strong>As of October 2024, the ideas and approaches of CIF had been disseminated with national audiences 13 times and featured in one peer-reviewed publication. Thirty-five institutions, including 26 National Cancer Institute-Designated Cancer Centers, had engaged in licensing CIF. In a user satisfaction survey among adopting institutions, a majority of individuals indicated they were gathering more data (91.7%) and requiring less effort to disseminate data (72.0%) using CIF than under their previous methods.</p><p><strong>Conclusions: </strong>CIF has demonstrated a broad and positive impact on cancer center catchment area surveillance in the 2 years since its release. CIF represents a high value, low-cost option for cancer centers wanting to build a cancer surveillance dashboard. The framework used for evaluating CIF's impact can be adapted to assess the impact of other open-source software built and distributed by cancer centers.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":"e35710"},"PeriodicalIF":6.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing trial recruitment science through enhanced study design. 通过改进研究设计推进试验招募科学。
IF 6.1 2区 医学
Cancer Pub Date : 2025-01-15 DOI: 10.1002/cncr.35703
Patrick Lewicki, Kristian Stensland
{"title":"Advancing trial recruitment science through enhanced study design.","authors":"Patrick Lewicki, Kristian Stensland","doi":"10.1002/cncr.35703","DOIUrl":"https://doi.org/10.1002/cncr.35703","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":"e35703"},"PeriodicalIF":6.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential new treatment approach for intermediate-stage hepatocellular carcinoma. 潜在的治疗中期肝细胞癌的新方法。
IF 6.1 2区 医学
Cancer Pub Date : 2025-01-15 DOI: 10.1002/cncr.35687
Mary Beth Nierengarten
{"title":"Potential new treatment approach for intermediate-stage hepatocellular carcinoma.","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35687","DOIUrl":"https://doi.org/10.1002/cncr.35687","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":"e35687"},"PeriodicalIF":6.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to "Advancing trial recruitment science through enhanced study design". 回复“通过强化研究设计推进试验招募科学”。
IF 6.1 2区 医学
Cancer Pub Date : 2025-01-15 DOI: 10.1002/cncr.35705
Krupa K Nathan, Angela B Smith
{"title":"Reply to \"Advancing trial recruitment science through enhanced study design\".","authors":"Krupa K Nathan, Angela B Smith","doi":"10.1002/cncr.35705","DOIUrl":"https://doi.org/10.1002/cncr.35705","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":"e35705"},"PeriodicalIF":6.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive impairment in patients with melanoma before adjuvant immune checkpoint inhibitor therapy and associations with brain gray matter, catechol-O-methyltransferase genotype, and psychological factors. 辅助免疫检查点抑制剂治疗前黑色素瘤患者的认知障碍与脑灰质、儿茶酚- o -甲基转移酶基因型和心理因素的关系
IF 6.1 2区 医学
Cancer Pub Date : 2025-01-15 Epub Date: 2024-12-11 DOI: 10.1002/cncr.35683
Josefine T Danielsen, Robert Zachariae, Henrik Schmidt, Jesper F Kallehauge, Julie K Thomadsen, Jeffrey S Wefel, Lisa M Wu, Ali Amidi
{"title":"Cognitive impairment in patients with melanoma before adjuvant immune checkpoint inhibitor therapy and associations with brain gray matter, catechol-O-methyltransferase genotype, and psychological factors.","authors":"Josefine T Danielsen, Robert Zachariae, Henrik Schmidt, Jesper F Kallehauge, Julie K Thomadsen, Jeffrey S Wefel, Lisa M Wu, Ali Amidi","doi":"10.1002/cncr.35683","DOIUrl":"10.1002/cncr.35683","url":null,"abstract":"<p><strong>Background: </strong>Cancer-related cognitive impairment (CRCI) is a significant concern in patients with cancer but understanding its prevalence and risk factors in patients with malignant melanoma (MMPs) remains limited. This study explores CRCI via a multifaceted approach integrating neurobiological, genetic, and psychological assessments.</p><p><strong>Methods: </strong>Cognitive functioning across multiple domains was assessed via neuropsychological tests in 47 MMPs before adjuvant immune checkpoint inhibitor therapy, compared with 53 matched healthy controls (HCs). Self-reported cognitive complaints, brain gray matter (GM) properties, catechol-O-methyltransferase (COMT) genotype, and psychological and behavioral factors were evaluated. Between-group differences were analyzed with t-tests and χ<sup>2</sup> tests, and associations were explored with correlation analyses. GM properties were assessed in a subset of 23 MMPs and 47 HCs.</p><p><strong>Results: </strong>MMPs exhibited significantly lower cognitive functioning across multiple tests (all p < .05), with a high CRCI prevalence (68.1% vs. 26.4% in HCs). MMPs reported higher fatigue, anxiety, and insomnia severity and poorer sleep quality and quality of life (all p < .01). Self-reported cognitive complaints in MMPs were associated with some cognitive test scores (all p < .05), fatigue (p < .001), and anxiety (p = .045). GM analyses revealed a smaller left cuneus volume in MMPs and significant associations between MMPs' processing speed and cortical thickness (right precentral and left inferior parietal regions) and between delayed verbal memory and right postcentral GM volume (all p < .01).</p><p><strong>Conclusions: </strong>These findings underscore the need for comprehensive assessments in MMPs to better understand and address CRCI. A multifaceted approach would provide valuable insights that could inform future interventions and improve patient outcomes and quality of life.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35683"},"PeriodicalIF":6.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142811627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to "De-escalation of axillary surgery in patients with sentinel lymph node micrometastases after neoadjuvant systemic therapy". 对 "新辅助系统疗法后前哨淋巴结微转移患者腋窝手术的升级 "的回复
IF 6.1 2区 医学
Cancer Pub Date : 2025-01-15 DOI: 10.1002/cncr.35699
Dong Seung Shin, Jai Min Ryu, Se Kyung Lee, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Byung Joo Chae
{"title":"Reply to \"De-escalation of axillary surgery in patients with sentinel lymph node micrometastases after neoadjuvant systemic therapy\".","authors":"Dong Seung Shin, Jai Min Ryu, Se Kyung Lee, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Byung Joo Chae","doi":"10.1002/cncr.35699","DOIUrl":"https://doi.org/10.1002/cncr.35699","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":"e35699"},"PeriodicalIF":6.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
National survey of financial burden and experience among patients with cancer and autoimmune disease receiving charitable copay assistance. 接受慈善共付援助的癌症和自身免疫性疾病患者的经济负担和经验的全国调查。
IF 6.1 2区 医学
Cancer Pub Date : 2025-01-15 DOI: 10.1002/cncr.35721
Jeffrey Peppercorn, Jill S Hasler, Bonnie Hu, Erin K Tagai, Greg J Zahner, Anh Lam, Sarina Robbins, Stephanie B Wheeler, Ryan D Nipp, Suzanne M Miller
{"title":"National survey of financial burden and experience among patients with cancer and autoimmune disease receiving charitable copay assistance.","authors":"Jeffrey Peppercorn, Jill S Hasler, Bonnie Hu, Erin K Tagai, Greg J Zahner, Anh Lam, Sarina Robbins, Stephanie B Wheeler, Ryan D Nipp, Suzanne M Miller","doi":"10.1002/cncr.35721","DOIUrl":"10.1002/cncr.35721","url":null,"abstract":"<p><strong>Background: </strong>Little is known about the role that charitable copay assistance (CPA) plays in addressing access to care and financial distress. The study sought to evaluate financial distress and experience with CPA among patients with cancer and autoimmune disease.</p><p><strong>Methods: </strong>This is a national cross-sectional self-administered anonymous electronic survey conducted among recipients of CPA to cover the costs of a drug for cancer or autoimmune disease. Self-reported financial distress as measured by Comprehensive Score for Financial Toxicity as well as health care spending and experience with financial barriers to care were evaluated, as were perspectives on policy questions related to CPA and costs of care.</p><p><strong>Results: </strong>Among 1566 respondents (1108 with cancer and 458 with autoimmune disease, median age 71, 51% female, 89% White, 69% household income <$60,000), 53% reported mild and 31% moderate/severe financial distress, despite CPA. Eighteen percent reported missing recommended care because of costs. Most respondents (96%) had Medicare, 55% reported supplemental insurance, and 66% believed that insurance would prevent them from facing high costs of health care. A total of 52% reported paying more than $100 monthly in drug costs and 41% spending more than 10% of monthly income on health care. Financial distress was similar among patients with cancer and autoimmune diseases. In multivariable regression analysis, younger age, less education, unemployment, higher comorbidity, and lower income were independently associated with higher financial distress.</p><p><strong>Conclusions: </strong>This study informs policy debate over the role of CPA foundations in the U.S. health insurance safety net and highlights the inadequacy of Medicare to guarantee access to care for older patients with chronic illness.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":"e35721"},"PeriodicalIF":6.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. 咖啡和茶的摄入与头颈癌的风险:国际头颈癌流行病学协会的最新汇总分析。
IF 6.1 2区 医学
Cancer Pub Date : 2025-01-15 Epub Date: 2024-12-23 DOI: 10.1002/cncr.35620
Timothy Nguyen, Alzina Koric, Chun-Pin Esther Chang, Christine Barul, Loredana Radoi, Diego Serraino, Mark P Purdue, Karl T Kelsey, Michael D McClean, Eva Negri, Valeria Edefonti, Kirsten Moysich, Zuo-Feng Zhang, Hal Morgenstern, Fabio Levi, Thomas L Vaughan, Carlo La Vecchia, Werner Garavello, Richard B Hayes, Simone Benhamou, Stimson P Schantz, Guo-Pei Yu, Hermann Brenner, Shu-Chun Chuang, Paolo Boffetta, Mia Hashibe, Yuan-Chin Amy Lee
{"title":"Coffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium.","authors":"Timothy Nguyen, Alzina Koric, Chun-Pin Esther Chang, Christine Barul, Loredana Radoi, Diego Serraino, Mark P Purdue, Karl T Kelsey, Michael D McClean, Eva Negri, Valeria Edefonti, Kirsten Moysich, Zuo-Feng Zhang, Hal Morgenstern, Fabio Levi, Thomas L Vaughan, Carlo La Vecchia, Werner Garavello, Richard B Hayes, Simone Benhamou, Stimson P Schantz, Guo-Pei Yu, Hermann Brenner, Shu-Chun Chuang, Paolo Boffetta, Mia Hashibe, Yuan-Chin Amy Lee","doi":"10.1002/cncr.35620","DOIUrl":"10.1002/cncr.35620","url":null,"abstract":"<p><strong>Introduction: </strong>The relations between coffee and tea consumption and head and neck cancer (HNC) incidence are unclear. With increasing global HNC burden, this study aims to examine the association between coffee, tea, and HNC.</p><p><strong>Methods: </strong>A pooled analysis of 9548 HNC cases and 15,783 controls from 14 individual-level case-control studies was conducted from the International Head and Neck Cancer Epidemiology consortium. Random-effects logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for HNC and its subsites, adjusting for sociodemographic and lifestyle factors.</p><p><strong>Results: </strong>Compared to non-coffee drinkers, drinking >4 cups of caffeinated coffee daily was inversely associated with HNC (OR, 0.83; 95% CI, 0.69-1.00), oral cavity (OR, 0.70; 95% CI, 0.55-0.89), and oropharyngeal cancers (OR, 0.78; 95% CI, 0.61-0.99). Drinking 3-4 cups of caffeinated coffee was inversely associated with hypopharyngeal cancer (OR, 0.59; 95% CI, 0.39-0.91). Drinking decaffeinated coffee and drinking between >0 to <1 cup daily were inversely associated with oral cavity cancer (OR, 0.75; 95% CI, 0.64-0.87 and OR, 0.66; 95% CI, 0.54-0.81). Drinking tea was inversely associated with hypopharyngeal cancer (OR, 0.71; 95% CI, 0.59-0.87). Daily tea consumption of >0 to ≤1 cup was inversely associated with HNC (OR, 0.91; 95% CI, 0.84-0.98) and hypopharyngeal cancer (OR, 0.73; 95% CI, 0.59-0.91), but drinking >1 cup was associated with laryngeal cancer (OR, 1.38; 95% CI, 1.09-1.74).</p><p><strong>Conclusion: </strong>These findings support reduced HNC risk among coffee and tea drinkers. Future studies are needed to address geographical differences in types of coffee and tea to improve our understanding of the association of coffee and tea and global HNC risk.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35620"},"PeriodicalIF":6.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142875540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信